MindMed Reassures Investors over Nasdaq Delisting Fears
In a Reddit AMA, MindMed CEO Robert Barrow says Nasdaq delisting is not “a risk of any sort.”
nasdaq
Psychedelic Business Spotlight: October 22
This week in psychedelic business news: UK fast tracks DMT for major depressive disorder; Field Trip Health expands its clinical presence in the US; and another psychedelic pharmaceuticals company prepares for the Nasdaq.
Psychedelic Business Spotlight: July 23, 2021
This week in psychedelic business news: Psychedelics as a treatment for obesity and TBIs, plus another psychedelic company inches toward listing on NYSE American stock exchange.
Third Psychedelic Stock ETF Coming Soon, Core One Labs Prepares to List on NASDAQ
Advisorshares Plant Medicine ETF will be listed on the NYSE Arca under the symbol PSIL.
Kevin O’Leary-Backed MindMed Will Be 2nd Psychedelic Company to List On Nasdaq
MindMed will take its Kevin O’Leary-backed platform onto the Nasdaq Tuesday as only the 2nd psychedelic company to do so.
Psychedelic Start-Up Atai Life Sciences to Raise $100 Million in IPO, 2nd to List on Nasdaq
Atai Life Sciences is now the second psychedelic company to list on Nasdaq, with plans to raise $100 million for its IPO.
End of content
End of content